Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy - sprookjes - yvandenbroek - TriplyDB

Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy

Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy

http://www.wikidata.org/entity/Q28324777

about

The therapeutic potential of cannabis and cannabinoids Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting Nausea: a review of pathophysiology and therapeutics Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy Chemotherapy-induced nausea and vomiting: optimizing prevention and management Marijuana Legalization: Impact on Physicians and Public Health Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system Intestinal and liver toxicity of antineoplastic drugs.A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.Nabilone: an alternative antiemetic for cancer chemotherapy.Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis.Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Cannabinoid Regulation of Acute and Anticipatory Nausea.Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting.2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.Pharmacologic treatment of chemotherapy-induced nausea and vomiting.Therapeutic potential of cannabinoids.Antiemetics and cytotoxic drugs Cannabinoids as antiemetics.Species specificity in the metabolism of nabilone. Relationship between toxicity and metabolic routes.Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.

P2860

Q24600806-8F49E5D1-A505-4A60-98AC-0AE7DB463D83 Q24607823-B0D9708A-FE55-42A6-8094-E6BDBE607664 Q26738288-B0F1E5E3-5F04-4F2F-88DC-547DF5BAEEA7 Q26771877-53735EAC-177E-4008-A18D-7389084E24FB Q26783177-1E9212EF-3E23-4595-94A7-F295E85A02ED Q26852601-5AF31E79-9588-4A6C-BBBE-296B640F6570 Q28082785-4EB2D061-B9D1-44BB-97BF-C8C613B0B5C1 Q28264258-78044D0D-4D4D-4CAB-A516-1AA05B6A54E8 Q28301264-8153F230-835E-4CDE-92DB-0FCB4E40B1A1 Q33605823-CD738725-8EED-4194-BFE5-35C62953DC48 Q34013540-A729E2B5-B53C-4F29-936D-0994BD54436F Q35602855-8481E59A-6270-4DC5-8D21-80734FD61507 Q35863912-382CB9C5-5100-4D14-80B5-332FC10E8836 Q36048236-6D94E909-740F-4A20-85CB-BF1B35A30FDA Q37215363-EF79BEE7-B8A7-40C0-9E8E-527FA182F9FE Q37761064-C44FD889-4BF6-4623-A406-1E99D485D6AF Q38208999-10240E70-7BAA-4574-9255-11D0805010B3 Q38503842-305E6D86-C783-408C-AF57-EF462E20E3A7 Q38598515-50B35F74-9722-40B2-9910-14B22F5A64E5 Q38943088-C4F8F415-5673-4434-9F83-83FA72E3C0DB Q38999263-3F234A13-D857-4C6F-8BF2-4074550B3792 Q40030462-91F40934-6CB5-4061-AF27-05879634D678 Q40078863-121BA556-03F5-4012-9356-6616EB30EC44 Q42336677-6485AA10-49C7-4B26-999E-59C437E3D9E6 Q42757858-8CE975EF-2143-49FE-825A-FA0FC5FDE12A Q42759375-B842DD55-8B18-4DC9-A52C-0A7AB51E61AC Q44828810-D260BC8A-5CCA-49F3-AF78-FD6B184716EB Q55333056-18BF4460-05B8-480B-8330-49C1747E98C5

P2860

Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy

http://www.wikidata.org/entity/Q28324777

description

1979 nî lūn-bûn

@nan

1979 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1979 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1979年の論文

@ja

1979年論文

@yue

1979年論文

@zh-hant

1979年論文

@zh-hk

1979年論文

@zh-mo

1979年論文

@zh-tw

1979年论文

@wuu

name

Superiority of nabilone over p ...... receiving cancer chemotherapy

@ast

Superiority of nabilone over p ...... receiving cancer chemotherapy

@en

Superiority of nabilone over p ...... receiving cancer chemotherapy

@nl

type

label

Superiority of nabilone over p ...... receiving cancer chemotherapy

@ast

Superiority of nabilone over p ...... receiving cancer chemotherapy

@en

Superiority of nabilone over p ...... receiving cancer chemotherapy

@nl

prefLabel

Superiority of nabilone over p ...... receiving cancer chemotherapy

@ast

Superiority of nabilone over p ...... receiving cancer chemotherapy

@en

Superiority of nabilone over p ...... receiving cancer chemotherapy

@nl

P1433

Q28324777-F8D6E8AC-E5EB-4D4E-A8F4-1EB7515CC530

P1476

Q28324777-6C2C945C-5643-4477-BD85-E0C72DB3704D

P2093

Q28324777-1588DF2F-A237-4547-8AC9-D55C8C62167E

Q28324777-479D95E3-CD5C-4ECF-8BD1-2F102F0EB8AA

Q28324777-64432D25-3B3A-4CBD-BEAC-151045B9A75E

Q28324777-752F1305-F2E5-4862-9ED8-D697635D5478

Q28324777-765B7698-F8CE-4218-8DBF-1154170BFAE1

Q28324777-8CC5CD6E-04E0-4A8D-8360-6A726F4C7021

Q28324777-BD86226B-0082-44EB-A556-A00F0ECE1666

Q28324777-C61CC0E5-AC3C-426D-9B94-0340406FD783

Q28324777-CE3C64CF-19D1-4A5E-95E7-19E1CE3CFA46

Q28324777-DC48A109-F047-4521-B880-B7CB9A139ED9

P304

Q28324777-B898B6EB-A653-42FC-9DF7-299179F8A186

P31

Q28324777-E32D2B03-430B-480A-AA56-3C332B4D06EE

P3181

Q28324777-7CC3F0EA-DE17-46B2-8E15-64095EB7C93F

P356

Q28324777-3419B9E5-39C6-42AB-B503-6820AD39BF6C

P407

Q28324777-55844A97-AF3A-475C-919C-2460F52C0B8C

P433

Q28324777-BC5DE0E1-5EF9-4A3E-9DD0-2E68287E2581

P478

Q28324777-592DEB97-647C-4EF5-95B2-AEA10F7F1ECE

P577

Q28324777-80005E0E-6D3F-484E-A525-98299AA65798

P698

Q28324777-230491DB-37FD-416F-A9A2-C555536FEE98

P921

Q28324777-8F8B3733-813C-4082-99B1-EBDF051DAC8E

P3181

P356

NEJM197906073002302

P1433

The New England Journal of Medicine

P1476

Superiority of nabilone over p ...... receiving cancer chemotherapy

@en

P2093

A B Chester

http://www.w3.org/2001/XMLSchema#string

B Furnas

http://www.w3.org/2001/XMLSchema#string

C Nagy

http://www.w3.org/2001/XMLSchema#string

J C Dean

http://www.w3.org/2001/XMLSchema#string

L H Einhorn

http://www.w3.org/2001/XMLSchema#string

R T Dorr

http://www.w3.org/2001/XMLSchema#string

S A Leigh

http://www.w3.org/2001/XMLSchema#string

S D Williams

http://www.w3.org/2001/XMLSchema#string

S E Jones

http://www.w3.org/2001/XMLSchema#string

T E Moon

http://www.w3.org/2001/XMLSchema#string

P304

1295-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4390950

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM197906073002302

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

300

http://www.w3.org/2001/XMLSchema#string

P577

1979-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

375088

http://www.w3.org/2001/XMLSchema#string

P921